Ratings Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:35:15 2024-04-26 am EDT			After market 12:02:27 pm
3 ^EUR	-1.32%		3.003	+0.10%

Apr. 22	Inventiva: UBS Group falls below 5% threshold	CF
Apr. 18	Transcript : Inventiva S.A. - Special Call

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
INVENTIVA	-26.74%	169M	-
VERTEX PHARMACEUTICALS INCORPORATED	-1.96%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.15%	95.71B	B+
ARGENX SE	+1.69%	22.02B	B
BIONTECH SE	-16.96%	20.9B	B+
GENMAB A/S	-9.30%	17.85B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.21B	A-
BEIGENE, LTD.	-14.81%	15.52B	B
NEUROCRINE BIOSCIENCES, INC.	+3.61%	13.86B	C+
SAREPTA THERAPEUTICS, INC.	+34.56%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes